Staidson Beijing Biopharma - Asset Resilience Ratio

Latest as of September 2022: 7.93%

Staidson Beijing Biopharma (300204) has an Asset Resilience Ratio of 7.93% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Staidson Beijing Biopharma (300204) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥130.40 Million

≈ $19.08 Million USD Cash + Short-term Investments

Total Assets

CN¥1.64 Billion

≈ $240.56 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2021)

This chart shows how Staidson Beijing Biopharma's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 300204 total asset value.

Liquid Assets Composition Over Time

This chart breaks down Staidson Beijing Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 300204 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥130.40 Million	7.93%
Total Liquid Assets	CN¥130.40 Million	7.93%

Asset Resilience Insights

Limited Liquidity: Staidson Beijing Biopharma maintains only 7.93% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Staidson Beijing Biopharma Industry Peers by Asset Resilience Ratio

Compare Staidson Beijing Biopharma's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Staidson Beijing Biopharma (2016–2021)

The table below shows the annual Asset Resilience Ratio data for Staidson Beijing Biopharma.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2021-12-31	20.88%	CN¥381.46 Million ≈ $55.82 Million	CN¥1.83 Billion ≈ $267.35 Million	-3.97pp
2020-12-31	24.85%	CN¥461.24 Million ≈ $67.49 Million	CN¥1.86 Billion ≈ $271.62 Million	+10.08pp
2019-12-31	14.77%	CN¥275.00 Million ≈ $40.24 Million	CN¥1.86 Billion ≈ $272.53 Million	-2.58pp
2018-12-31	17.35%	CN¥480.85 Million ≈ $70.36 Million	CN¥2.77 Billion ≈ $405.65 Million	+6.80pp
2017-12-31	10.54%	CN¥277.10 Million ≈ $40.55 Million	CN¥2.63 Billion ≈ $384.64 Million	-15.32pp
2016-12-31	25.86%	CN¥607.86 Million ≈ $88.95 Million	CN¥2.35 Billion ≈ $343.97 Million	--

pp = percentage points

About Staidson Beijing Biopharma

SHE:300204 China Biotechnology

Market Cap

$1.57 Billion

CN¥10.75 Billion CNY

Market Cap Rank

#7096 Global

#1513 in China

Share Price

CN¥19.85

Change (1 day)

+1.28%

52-Week Range

CN¥19.40 - CN¥39.90

All Time High

CN¥61.00